Nektar Therapeutics (NASDAQ:NKTR)’s traded shares stood at 2.36 million during the last session, with the company’s beta value hitting 0.60. At the close of trading, the stock’s price was $1.17, to imply a decrease of -8.59% or -$0.11 in intraday trading. The NKTR share’s 52-week high remains $1.93, putting it -64.96% down since that peak but still an impressive 64.1% since price per share fell to its 52-week low of $0.42. The company has a valuation of $215.82M, with an average of 2.09 million shares in intraday trading volume over the past 10 days and average of 1.20 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Nektar Therapeutics (NKTR), translating to a mean rating of 2.71. Of 3 analyst(s) looking at the stock, 0 analyst(s) give NKTR a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.2.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Nektar Therapeutics (NASDAQ:NKTR) trade information
After registering a -8.59% downside in the last session, Nektar Therapeutics (NKTR) has traded red over the past five days. The 5-day price performance for the stock is -14.60%, and -15.22% over 30 days. With these gigs, the year-to-date price performance is 107.08%. Short interest in Nektar Therapeutics (NASDAQ:NKTR) saw shorts transact 5.23 million shares and set a 3.91 days time to cover.
The extremes give us $6 and $24 for target low and target high price respectively. As such, NKTR has been trading -1951.28% off suggested target high and -412.82% from its likely low.
Nektar Therapeutics (NKTR) estimates and forecasts
Looking at statistics comparing Nektar Therapeutics share performance against respective industry, we note that the company has outperformed competitors. Nektar Therapeutics (NKTR) shares are -35.00% down over the last 6 months, with its year-to-date growth rate higher than industry average at 47.59% against 16.40%. Revenue is forecast to grow 10.36% this quarter before falling -19.57% for the next one. The rating firms project that company’s revenue will grow 8.90% compared to the previous financial year.
Revenue forecast for the current quarter as set by 7 analysts is 29.91M. Meanwhile, for the current quarter, a total of 3 analyst(s) estimate revenue growth to 24.03M.Earnings reports from the last fiscal year show that sales brought in 23.89M and 21.64M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 25.21% before jumping 11.06% in the following quarter.
NKTR Dividends
Nektar Therapeutics has its next earnings report out in December. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Nektar Therapeutics (NASDAQ:NKTR)’s Major holders
Nektar Therapeutics insiders hold 1.05% of total outstanding shares, with institutional holders owning 75.65% of the shares at 76.45% float percentage. In total, 75.65% institutions holds shares in the company, led by DEEP TRACK CAPITAL, LP. As of 2024-06-30, the company held over 17.88 million shares (or 9.1789% of shares), all amounting to roughly $22.17 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 15.16 million shares, or about 7.7823% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $18.79 million.
